Press Release Title Background

Virtual Clinical Trials Market to Grow at a CAGR of 6.22% During 2026 to 2035; Driven by Increasing Adoption of Digital Technologies and Decentralized Clinical Research

Report Details:
15 Companies Covered
200 Pages

Virtual Clinical Trials Market Highlights


Virtual Clinical Trials Market size was valued at USD 9.3 Billion in 2024. The market is projected to grow from USD 9.879 Billion in 2025 to USD 18.07 Billion by 2035, exhibiting a CAGR of 6.22% during the forecast period 2026-2035. 


Virtual clinical trials are method of conducting clinical research using apps, electronically monitoring devices and online social engagement platformsThis exponential increase in number of clinical trials monitored digitally is expected to increase the growth of global virtual clinical trials market during the forecast period.


The global virtual clinical trials market is currently dominated by several market players. , Tabula Rasa HealthCare (US), a New Jersey-based company collaborated with Washington-based health plan provider Regence (US) to virtually trial several different COVID-19 drug candidates and assess the risk of adverse drug events. Regence will provide de-identified medical information from about 500,000 of its members to Tabula Rasa HealthCare. Thus, an increasing number of healthcare companies collaborating with technology companies to leverage data-driven clinical studies for development of effective medication by monitoring trials remotely is increasing global virtual clinical trials market size.
The demand created by pandemic for adoption of monitoring trials remotely is expected to increase the lucrativeness of virtual clinical trials market during the forecast period.


Regional Analysis


The market has been divided, by region, into the North America, Europe, Asia-Pacific, and Rest of the World.


North America is anticipated to hold the largest market share owing to availability of major players operating in the region. Medable, Inc. (US), Oracle Corporation (US), IQVIA Holdings, Inc. (US), Syneos Health (US), PPD, Inc. (US) and Medpace Holdings, Inc. (US) are some of the notable companies operating in the region. Moreover, collaborative approach by companies operating in the region were observed due to rising demand and continuation of early phase clinical studying during the pandemic. For instance, during October 2020, FHI Clinical Inc. (US), a contract research organization adopted Oracle’s (US) Oracle Health Sciences Clinical One, a cloud platform for effective study management throughout the entire drug development lifecycle. FHI clinical also uses Oracle Argus Safety for safety case management; Oracle Clinical Trial Management System Cloud Service to manage the research portfolio; and Oracle ClearTrial Cloud Service to manage projects. Thus, increasing adoption of cloud-based platforms by contract research organizations operating in the region are anticipated to fuel the growth of virtual clinical trials market. The virtual clinical trials market in North America is divided into the US and Canada.


European virtual clinical trials market has been categorized into Germany, France, the UK, Italy, Spain, and the rest of Europe. Europe is anticipated to hold the significant market share owing to investment activities related to clinical trials in the region and support from government for R&D.  announced a strategic partnership between its Early Phase Clinical Unit (Germany) and Clinical Trial Center (CTC) North, a full-service CRO located at the University Medical Center Hamburg-Eppendorf (Germany). Parexel intends to roll-out and implement eSource system ClinBase at CTC North to drive efficiency. An increasing number of research institutes partnering with leading clinical trial services provider to accelerate development of products for different conditions such as cancer, COVID-19 and other disorders is expected to fuel growth of virtual clinical trials market during the forecast period. Moreover, ongoing research studies being converted to virtual mode are expected to increase the demand for IT services, thereby generating opportunities for IT companies to access virtual clinical trials market. Thus, long-term partnerships among research institutes and service providers to accelerate ongoing research studies is anticipated to increase the lucrativeness of virtual clinical trials market in the region during the forecast period.


Segmentation


The global virtual clinical trials market has been segmented based on study type, phase, and indication.


The market, based on study type, has been divided into interventional, observational and others. The interventional segment is likely to hold maximum market share in the global virtual clinical trials market owing to its larger utility and recruitment of patients for testing novel drugs.


The virtual clinical trials market based on phase has been segmented into Phase 1, Phase 2, Phase 3 and Phase 4. The Phase 1 segment is likely to hold significant share in the market as every clinical trial study proceeds through Phase 1.


The virtual clinical trials market based on indication has been segmented into oncology, cardiovascular, immunology, gastrointestinal, respiratory, endocrinology, ophthalmology and others. The oncology segment is likely to hold the largest share in the market due to larger number of clinical trials focused on finding treatment options for cancer.


Key Players


Some of the key players in the global virtual clinical trials market are Oracle Corporation (US), IQVIA Holdings, Inc. (US), Dassault Systemes SE (France), Medpace Holdings, Inc. (US), Icon plc (Ireland), Laboratory Corporation of America Holdings (US), Parexel International Corporation (US), Medable, Inc. (US), Clinical Ink, Inc. (US), Wuxi AppTech (China), and Medable, Inc. (US) among others.